Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

Background For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown. Despite improved outcomes with 12 months of durvalumab, which has become the standard of care, new strategies to improve surv...

Descripció completa

Dades bibliogràfiques

Autors principals:	Borys Hrinczenko, Jarushka Naidoo, Jason Chesney, Salma K Jabbour, Naomi Fujioka, Greg Durm, Apar Kishor Ganti, Hirva Mamdani, Mary Jo Fidler, Nasser H Hanna, Shadia Jalal, Ticiana A Leal, Sandra Althouse, Susan Perkins, Lawrence Feldman
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2025-07-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/13/7/e010316.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!